Antiviral treatment of cytomegalovirus infection: An update

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 5, 2012, Pages 623-627

  Härter, Georg ^a   Michel, Detlef ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Antiviral treatment; Cytomegalovirus; Ganciclovir; Resistance; Virus evolution

Indexed keywords

AIC 246; ANTIVIRUS AGENT; ARTESUNATE; BENZIMIDAVIR; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; CYCLOPROPAVIR; FOSCARNET; GANCICLOVIR; LEFLUNOMIDE; LETERMOVIR; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIVIRAL RESISTANCE; CD8+ T LYMPHOCYTE; CELL THERAPY; CYTOMEGALOVIRUS INFECTION; DNA SEQUENCE; GENE MUTATION; GENOTYPE; HIGH RISK PATIENT; HUMAN; KIDNEY TRANSPLANTATION; MASS SPECTROMETRY; PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PYROSEQUENCING; REVIEW; VIRAL CLEARANCE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; GANCICLOVIR; HUMANS;

EID: 84858663475     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.658775     Document Type: Review

References (30)

1. Schreiber A, Harter G, Schubert A, et al. Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin Pharmacother 2009;10:191-209
2. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010;89:779-95
3. Hantz S, Garnier-Geoffroy F, Mazeron MC, et al. Drug-resistant cytomegalovirus in transplant recipients: A French cohort study. J Antimicrob Chemother 2010;65:2628-40
4. Myhre HA, Haug DD, Kristiansen KI, et al. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. Transplantation 2011;92:217-23
5. Van Der Beek MT, Berger SP, Vossen AC, et al. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: Comparison of treatment failure and antiviral resistance. Transplantation 2010;89:320-6
6. Humar A, Limaye AP, Blumberg EA, et al. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: Two-year results of the IMPACT study. Transplantation 2010;90:1427-31
7. Couzi L, Helou S, Bachelet T, et al. High incidence of anticytomegalovirus drug resistance among D+R- kidney transplant recipients receiving preemptive therapy. Am J Transplant 2011;published online; doi: 10.1111/ j.1600-6143.2011.03766.x
8. Kampmann SE, Schindele B, Apelt L, et al. Pyrosequencing allows the detection of emergent ganciclovir resistance mutations after HCMV infection. Med Microbiol Immunol 2011;200:109-13
9. Schindele B, Apelt L, Hofmann J, et al. Improved detection of mutated human cytomegalovirus UL97 by pyrosequencing. Antimicrob Agents Chemother 2010;54:5234-41
10. Gorzer I, Guelly C, Trajanoski S, Puchhammer-Stockl E. Deep sequencing reveals highly complex dynamics of human cytomegalovirus genotypes in transplant patients over time. J Virol 2010;84:7195-203
11. Posthuma CC, Van Der Beek MT, Van Der Blij-De Brouwer CS, et al. Mass spectrometry-based comparative sequencing to detect ganciclovir resistance in the UL97 gene of human cytomegalovirus. J Clin Virol 2011;51:25-30
12. Iwasenko JM, Scott GM, Naing Z, et al. Diversity of antiviral-resistant human cytomegalovirus in heart and lung transplant recipients. Transpl Infect Dis 2011;13:145-53
13. Atkinson C, Emery VC. Cytomegalovirus quantification: where to next in optimising patient management? J Clin Virol 2011;51:223-8
14. Hakki M, Chou S. The biology of cytomegalovirus drug resistance. Curr Opin Infect Dis 2011;24:605-11
15. Boutolleau D, Burrel S, Agut H. Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. Antiviral Res 2011;91:32-5
16. Chevillotte M, von Einem J, Meier BM, et al. A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes. Antiviral Res 2010;85:318-27
17. Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: A phase III, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011;11:284-92
18. Avery RK, Marty FM, Strasfeld L, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis 2010;12:489-96
19. Strasfeld L, Lee I, Tatarowicz W, et al. Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir. J Infect Dis 2010;202:104-8
20. Avery RK, Mossad SB, Poggio E, et al. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation 2010;90:419-26
21. A multicenter, open-label study of CMX- 001 treatment of serious diseases or conditions caused by dsDNA Viruses. Available from ct2/show/NCT01143181 Last accessed 7 November 2011
22. Chou S, Bowlin TL. Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. Antimicrob Agents Chemother 2011;55:382-4
23. Chou S, Marousek G, Bowlin TL. Cyclopropavir Susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. Antimicrob Agents Chemother 2011;56:197-201
24. Wolf DG, Shimoni A, Resnick IB, et al. Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antiviral Res 2011;90:183-6
25. Lau PK, Woods ML, Ratanjee SK, John GT. Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection. Clin Infect Dis 2011;52:279
26. Lischka P, Hewlett G, Wunberg T, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother 2010;54:1290-7
27. Goldner T, Hewlett G, Ettischer N, et al. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol 2011;85:10884-93
28. Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 2011;11:1079-84
29. Mui TS, Kapp M, Einsele H, Grigoleit GU. T-cell therapy for cytomegalovirus infection. Curr Opin Organ Transplant 2010;published online; doi: 10.1097/ MOT.0b013e32834016b9
30. Schmitt A, Tonn T, Busch DH, et al. Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T-cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 2011;51:591-9